The future of pathology isn’t just digital—it’s integrated. As precision medicine continues to advance, the need for seamless coordination between pathology and molecular diagnostics has never been greater. However, traditional workflows tend to have bottlenecks that slow down critical insights, impacting patient care. That’s why Lumea has transformed the diagnostic process by embedding molecular testing directly into its digital pathology platform, ensuring faster, more efficient, and more reliable access to crucial test results.
Beyond the “Cockpit” Approach: A True Centralized Diagnostic Platform
Many in the industry refer to pathology software as an “IMS Cockpit,” a hub where diagnostics converge. But at Lumea, we see it differently. Rather than acting as a cockpit that displays information from multiple sources on multiple screens or windows that a person has to toggle between, our digital pathology platform is designed to be a single-screen, centralized diagnostic platform that follows the patient’s journey from tissue collection through diagnosis, prognosis, and treatment planning.
By embedding molecular test ordering within the digital pathology workflow, we remove silos and inefficiencies, making it easier, faster, and more reliable for both clinicians and pathologists to get the answers they need. These integrations ensure that molecular testing isn’t an afterthought–it’s a seamless part of the diagnostic process from the start.
Faster Turnaround Times = Faster Treatment Decisions
Time matters in patient care. Our integrated workflow in Viewer+™ allows molecular tests to be ordered, processed, and returned more quickly than ever before, reducing turnaround times by more than 50% in some cases. Faster results mean faster decision-making and improved treatment pathways.
How is ordering accelerated? With Lumea’s conditional ordering feature. Physicians can set up auto-requests for molecular tests based on specific requirements, ensuring that necessary tests are ordered without extra steps. As soon as a patient meets the pre-determined criteria, at any point in the diagnostic process, the designated test orderer gets a notification that the test has been requested and approved by the physician. All the orderer needs to do is finalize the request, and a notification in the system is sent to the lab to begin prepping the next steps. This automation eliminates delays and significantly improves efficiency.
Fewer Dropped Tests = Get Patients the Care They Deserve
A key problem in traditional pathology workflows is that sometimes molecular tests are forgotten or unordered due to communication gaps between surgical centers, labs, and pathologists. By embedding test ordering directly into the digital pathology platform, we reduce the risk of missed or dropped tests, ensuring that every patient receives the maximum diagnostic insights they need.
Better Tissue Quality = Lower QNS Rates
Pairing Lumea’s physical technology with its digital technology further improves patient care. How?
One of the biggest challenges in molecular diagnostics is quantity not sufficient (QNS) rates, where a sample lacks enough material for analysis. Lumea’s advanced tissue-handling technology has demonstrated a 14.5% average increase in histologic tissue surface area on the glass slide and a 31.8% average increase in biopsy core length in some tissue types. These improvements mean more usable tissue for molecular testing, reducing the likelihood of insufficient samples and improving diagnostic accuracy.
The Future of Pathology is Integrated
Digital pathology and molecular diagnostics shouldn’t exist in separate workflows–they should work together as part of a unified approach to patient care. At Lumea, we believe that precision medicine begins with precision pathology, and molecular testing is an essential piece of that puzzle.
By making molecular diagnostics a seamless, integrated part of the pathology workflow, we’re not just optimizing lab efficiency–we’re ensuring that patients receive faster, more accurate diagnoses and better outcomes.
This is the future of pathology.
